Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study

Serotonin 1A (5-HT1A) receptors are involved in several physiological and pathological processes and constitute therefore an important therapeutic target. The recent pharmacological concept of biased agonism asserts that highly selective agonists can preferentially direct receptor signaling to specific intracellular responses, opening the possibility of drugs targeting a receptor subtype in specific brain regions. The present study brings additional support to this concept thanks to functional magnetic resonance imaging (7 Tesla-fMRI) in anaesthetized rats. Three 5-HT1A receptor agonists (8-OH-DPAT, F13714 and F15599) and one 5-HT1A receptor antagonist (MPPF) were compared in terms of influence on the brain blood oxygen level-dependent (BOLD) signal. Our study revealed for the first time contrasting BOLD signal patterns of biased agonists in comparison to a classical agonist and a silent antagonist. By providing functional information on the influence of pharmacological activation of 5-HT1A receptors in specific brain regions, this neuroimaging approach, translatable to the clinic, promises to be useful in exploring the new concept of biased agonism in neuropsychopharmacology.

[1]  T. Suda,et al.  [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease]. , 2002, No to shinkei = Brain and nerve.

[2]  Francesco de Pasquale,et al.  Differential response to specific 5-Ht(7) versus whole-serotonergic drugs in rat forebrains: A phMRI study , 2011, NeuroImage.

[3]  H. Meltzer,et al.  The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats , 2012, Psychopharmacology.

[4]  L. Voronin,et al.  Long-term potentiation in the hippocampus , 1983, Neuroscience.

[5]  W. Koek,et al.  Possible in vivo 5‐HT reuptake blocking properties of 8‐OH‐DPAT assessed by measuring hippocampal extracellular 5‐HT using microdialysis in rats , 1996, British journal of pharmacology.

[6]  R. Lefkowitz,et al.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.

[7]  T. Kenakin.  Biased signalling and allosteric machines: new vistas and challenges for drug discovery , 2012, British journal of pharmacology.

[8]  M. Pompeiano,et al.  Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  A. Newman-Tancredi,et al.  Rapid desensitization of somatodendritic 5‐HT1A receptors by chronic administration of the high‐efficacy 5‐HT1A agonist, F13714: a microdialysis study in the rat , 2006, British journal of pharmacology.

[10]  Nicolas Costes,et al.  A Multi-Atlas Based Method for Automated Anatomical Rat Brain MRI Segmentation and Extraction of PET Activity , 2014, PloS one.

[11]  P. Pauwels,et al.  5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. , 2001, European journal of pharmacology.

[12]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[13]  A. Newman-Tancredi,et al.  Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia , 2015, Neuropharmacology.

[14]  R. Depoortère,et al.  F15599, a preferential post-synaptic 5-HT1A receptor agonist: Activity in models of cognition in comparison with reference 5-HT1A receptor agonists , 2010, European Neuropsychopharmacology.

[15]  R. Andrade,et al.  5-HT1A Receptor-Mediated Autoinhibition and the Control of Serotonergic Cell Firing. , 2015, ACS chemical neuroscience.

[16]  Mustapha Riad,et al.  Immunocytochemical localization of serotonin1A receptors in the rat central nervous system , 1996, The Journal of comparative neurology.

[17]  Seong-Gi Kim,et al.  Relationship between neural, vascular, and BOLD signals in isoflurane-anesthetized rat somatosensory cortex. , 2006, Cerebral cortex.

[18]  R. Elliott,et al.  Neuronal effects of acute citalopram detected by pharmacoMRI , 2005, Psychopharmacology.

[19]  J. Barrett,et al.  Lecozotan (SRA-333): A Selective Serotonin 1A Receptor Antagonist That Enhances the Stimulated Release of Glutamate and Acetylcholine in the Hippocampus and Possesses Cognitive-Enhancing Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.

[20]  René Hen,et al.  5-HT1A Autoreceptor Levels Determine Vulnerability to Stress and Response to Antidepressants , 2010, Neuron.

[21]  R. Schreiber,et al.  Divergent effects of the ‘biased’ 5‐HT1A receptor agonists F15599 and F13714 in a novel object pattern separation task , 2015, British journal of pharmacology.

[22]  A. Newman-Tancredi,et al.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties , 2011, Psychopharmacology.

[23]  A. Newman-Tancredi.  The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. , 2010, Current opinion in investigational drugs.

[24]  G. Kronenberg,et al.  The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants , 2016, Journal of psychopharmacology.

[25]  Shitij Kapur,et al.  Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. , 2007, The American journal of psychiatry.

[26]  P. Blier,et al.  Is there a role for 5-HT1A agonists in the treatment of depression? , 2003, Biological Psychiatry.

[27]  A. Newman-Tancredi,et al.  Contrasting Contribution of 5-Hydroxytryptamine 1A Receptor Activation to Neurochemical Profile of Novel Antipsychotics: Frontocortical Dopamine and Hippocampal Serotonin Release in Rat Brain , 2005, Journal of Pharmacology and Experimental Therapeutics.

[28]  Rafael Delgado y Palacios,et al.  Different anesthesia regimes modulate the functional connectivity outcome in mice , 2014, Magnetic resonance in medicine.

[29]  Angelo Bifone,et al.  Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics , 2012, Expert opinion on drug discovery.

[30]  J. Sprouse,et al.  8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production , 2004, Neuropharmacology.

[31]  P. Heusler,et al.  Signal transduction and functional selectivity of F15599, a preferential post‐synaptic 5‐HT1A receptor agonist , 2009, British journal of pharmacology.

[32]  Nicola R. Sibson,et al.  Pharmacological MRI in animal models: A useful tool for 5-HT research? , 2008, Neuropharmacology.

[33]  P. Celada,et al.  Preferential in vivo action of F15599, a novel 5‐HT1A receptor agonist, at postsynaptic 5‐HT1A receptors , 2010, British journal of pharmacology.

[34]  R. Elliott,et al.  Assessing human 5-HT function in vivo with pharmacoMRI , 2008, Neuropharmacology.

[35]  Luc Zimmer,et al.  [18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  F. Colpaert,et al.  High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. , 2007, Journal of medicinal chemistry.

[37]  F. Colpaert,et al.  Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: A quantitative ELISA study , 2009, Neuropharmacology.

[38]  H. Kung,et al.  4-(2'-Methoxy-phenyl)-1-[2'-(n-2"-pyridinyl)-p-iodobenzamido]-ethyl- piperazine ([125I]p-MPPI) as a new selective radioligand of serotonin-1A sites in rat brain: in vitro binding and autoradiographic studies. , 1995, The Journal of pharmacology and experimental therapeutics.

[39]  John T. Williams,et al.  A selective 5-HT1a receptor agonist improves respiration in a mouse model of Rett syndrome. , 2013, Journal of applied physiology.

[40]  A. Newman-Tancredi.  Biased agonism at serotonin 5-HT 1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders , 2011 .

[41]  L. Swanson.  The Rat Brain in Stereotaxic Coordinates, George Paxinos, Charles Watson (Eds.). Academic Press, San Diego, CA (1982), vii + 153, $35.00, ISBN: 0 125 47620 5 , 1984 .

[42]  O. Arthurs,et al.  How well do we understand the neural origins of the fMRI BOLD signal? , 2002, Trends in Neurosciences.

[43]  M. Hamon,et al.  125I-Bolton-Hunter-8-methoxy-2-[N-propyl-N-propylamino]tetralin as a new selective radioligand of 5-HT1A sites in the rat brain. In vitro binding and autoradiographic studies. , 1988, The Journal of pharmacology and experimental therapeutics.

[44]  Yasuhiro Kaneda,et al.  Serotonin receptors : their key role in drugs to treat schizophrenia , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[45]  M. Carli,et al.  8‐Hydroxy‐2‐(di‐n‐propylamino)tetralin impairs spatial learning in a water maze: role of postsynaptic 5‐HT1A receptors , 1992, British journal of pharmacology.

[46]  L. Lanfumey,et al.  Regional Differences in the Coupling of 5-Hydroxytryptamine-1A Receptors to G Proteins in the Rat Brain , 2006, Molecular Pharmacology.

[47]  L. Schechter,et al.  The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. , 2002, Current pharmaceutical design.

[48]  M. Kleven,et al.  Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors. , 1999, Journal of medicinal chemistry.

[49]  M. Erlander,et al.  A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.

[50]  S. Fox.  Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease , 2013, Drugs.

[51]  T. Duong,et al.  Regional Cerebral Blood Flow and BOLD Responses in Conscious and Anesthetized Rats under Basal and Hypercapnic Conditions: Implications for Functional MRI Studies , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[52]  G. Meco,et al.  Buspirone in levodopa-induced dyskinesias. , 1994, Clinical neuropharmacology.

[53]  R. Depoortère,et al.  F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. , 2010, The international journal of neuropsychopharmacology.

[54]  H. Kung,et al.  Synthesis and evaluation of 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridinyl)-p- iodobenzamido]ethyl]piperazine (p-MPPI): a new iodinated 5-HT1A ligand. , 1994, Journal of medicinal chemistry.

[55]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[56]  C. de Montigny,et al.  Long-Term Antidepressant Treatments Result in a Tonic Activation of Forebrain 5-HT1A Receptors , 1998, The Journal of Neuroscience.

[57]  Angelo Bifone,et al.  In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI , 2007, NeuroImage.